Q-omics provides the consensus-scored MTATP6P23 profile across patient tissues and cancer cell-line models. MTATP6P23 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MTATP6P23 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, MTATP6P23 RNA expression shows 8,958 significant gene co-expression associations, with the highest sampling consensus in THCA. Together, these results highlight STAD, KICH, and THCA as cancer lineages where MTATP6P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P23 survival associations across molecular data types. MTATP6P23 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P23 RNA expression–survival associations across cancer types. High MTATP6P23 expression shows unfavorable associations in STAD, KIRC, ESCA, READ, PAAD and UCEC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for MTATP6P23 RNA expression.
This table summarizes MTATP6P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P23 shows higher tumor expression in KICH. The KICH box plot shows higher MTATP6P23 RNA expression in tumor versus normal tissue (log2 FC = +0.149, t-test p = .008).
This table shows molecular features associated with MTATP6P23 in patient tissues and cancer cell lines. In patient samples, MTATP6P23 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
